MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
9.67%
Quick Ratio
9.67%
Cash Ratio
8.75%
Debt to Asset Ratio
1023.05%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Prepaid expenses and other curre...
    • Other
Liabilities Breakdown
    • Accumulated deficit
    • Additional paid-in capital
    • Total current liabilities
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
13,269
14,111
17,720
11,525
Prepaid expenses and other current assets
1,390
1,580
1,716
1,204
Total current assets
14,659
15,691
19,436
12,729
Other
167
68
96
136
Total assets
14,826
15,759
19,532
12,865
Accounts payable
3,727
3,121
3,245
5,390
Accrued expenses
3,993
4,186
4,722
5,038
Convertible notes payable and accrued interest, net of debt discounts related party (note 3)
33,043
-
0
32,521
Derivative liabilities (note 5)
6,135
-
0
3,742
Borrowing and accrued interest under convertible line of credit, net of debt discount related party (note 9)
104,659
-
-
-
Borrowing and accrued interest under convertible lines of credit, net of debt discount related party (note 9)
-
-
-
89,754
Accrued dividends payable
62
0
63
0
Total current liabilities
151,619
7,307
8,030
136,445
Convertible notes payable and accrued interest, net of debt discounts related party (note 3)
0
32,878
32,702
0
Derivative liabilities (note 5)
0
2,979
3,962
0
Borrowing and accrued interest under convertible line of credit, net of debt discount related party (note 9)
0
102,832
101,033
0
Other
59
-
-
-
Total liabilities
151,678
145,996
145,727
136,445
Series c 6 super dividend redeemable convertible preferred stock 1,000 shares authorized, 176 issued and outstanding at june 30, 2026 and december 31, 2025, redemption value 7,966,000, liquidation value 1,760,000 at june 30, 2026
1,723
1,723
1,723
1,723
Series a 12 convertible preferred stock 1,742,500 shares authorized, 1,185,000 and 1,210,000 issued and outstanding at june 30, 2026 and december 31, 2025, respectively, liquidation value 1,185,000 at june 30, 2026
480
480
490
490
Common stock, 0.001 par value 150,000,000 shares authorized at june 30, 2026 and december 31, 2025, 66,311,910 and 65,201,995 issued and outstanding at june 30, 2026 and december 31, 2025, respectively
66
65
65
64
Additional paid-in capital
307,667
305,108
304,073
301,127
Accumulated deficit
-446,788
-437,613
-432,546
-426,984
Total stockholders deficit
-138,575
-131,960
-127,918
-125,303
Total liabilities, redeemable convertible preferred stock and stockholders deficit
14,826
15,759
19,532
12,865
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$13,269K (-3.65%↓ Y/Y)Prepaid expenses andother current assets$1,390K (-16.06%↓ Y/Y)Total current assets$14,659K (-4.98%↓ Y/Y)Other$167K (-4.57%↓ Y/Y)Total assets$14,826K (-4.97%↓ Y/Y)Accumulated deficit-$446,788K (-6.69%↓ Y/Y)Total liabilities,redeemable convertible...$14,826K (-4.97%↓ Y/Y)Total stockholdersdeficit-$138,575K (-16.56%↓ Y/Y)Additional paid-in capital$307,667K (2.79%↑ Y/Y)Series a 12 convertiblepreferred stock 1,742,500...$480K (-2.04%↓ Y/Y)Common stock, 0.001 parvalue 150,000,000...$66K (4.76%↑ Y/Y)Total liabilities$151,678K (14.24%↑ Y/Y)Series c 6 superdividend redeemable...$1,723K (0.00%↑ Y/Y)Total currentliabilities$151,619K (1307.27%↑ Y/Y)Other$59K Borrowing and accruedinterest under...$104,659K Convertible notes payableand accrued...$33,043K Derivative liabilities(note 5)$6,135K Accrued expenses$3,993K (-17.60%↓ Y/Y)Accounts payable$3,727K (-36.45%↓ Y/Y)Accrued dividendspayable$62K (-1.59%↓ Y/Y)

GALECTIN THERAPEUTICS INC (GALT)

GALECTIN THERAPEUTICS INC (GALT)